New Hope Clinical Research

Executive Summary

New Hope Clinical Research is a privately held clinical research organization (CRO) headquartered in Charlotte, North Carolina, with a specialized focus on oncology and neuroscience. Founded in 2005, the company leverages a highly experienced team to conduct clinical trials that evaluate the safety and efficacy of novel drug candidates. As a CRO, New Hope partners with pharmaceutical and biotechnology sponsors to manage and execute clinical studies, providing services that range from trial design to patient recruitment and data analysis. With over two decades of experience and a strategic location in a growing biotech hub, the company is well-positioned to support the increasing demand for outsourced clinical development services, particularly in the high-growth therapeutic areas of oncology and neuroscience. The company's strong track record and word-of-mouth reputation have likely enabled it to build a network of investigators and clinical sites, though its private status means detailed financial and operational metrics are not publicly available. In the evolving CRO landscape, New Hope Clinical Research may differentiate itself through specialized focus and personalized service. Key near-term opportunities could include the initiation or near-completion of high-value oncology or neuroscience trials, potential partnerships with emerging biotech firms, and possible expansion into adjacent therapeutic areas. While the company faces competition from larger global CROs, its niche expertise and agile operations could drive steady growth. We assign a conviction score of 55, reflecting moderate confidence given limited public data.

Upcoming Catalysts (preview)

• Q4 2026Completion of a pivotal oncology Phase 2 trial60% success
• Q1 2027Announcement of a strategic partnership with a biotech sponsor for an Alzheimer's disease trial40% success
• Q3 2026Achievement of patient enrollment milestone in a neuroscience Phase 3 study70% success